ProCE Banner Activity

INFORM: Randomized Phase II Study of Neoadjuvant Cisplatin vs AC in Newly Diagnosed Breast Cancer With Germline BRCA Mutations

Slideset Download
Conference Coverage
In the randomized phase II INFORM trial, rates of pCR and RCB 0/1 were similar with cisplatin vs AC in patients with early-stage breast cancer and germline BRCA mutations.

Released: December 17, 2019

Expiration: December 15, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen